Durvalumab consolidates treatment breakthroughs: Significantly prolongs the survival of confined small cell lung cancer 26/09/2025
A new choice for cervical cancer immunotherapy! PD-1 new drug Balstilimab is qualified for priority review by the FDA 20/06/2022 Cervical cancer PD-L1 gene, PD-L2 gene
Poor response to immunotherapy in advanced tumors? New generation dual immunotherapy offers long-lasting anti-cancer activity. 07/06/2022 晚期腫瘤 PD-1/PD-L1
